Evoke Pharma (NASDAQ:EVOK) Announces Earnings Results

Evoke Pharma (NASDAQ:EVOK) posted its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, hitting the consensus estimate of ($0.45), FiscalAI reports. The firm had revenue of $4.28 million during the quarter, compared to analyst estimates of $4.33 million. Evoke Pharma had a negative return on equity of 90.87% and a negative net margin of 36.23%.

Evoke Pharma Stock Performance

Shares of NASDAQ:EVOK remained flat at $10.69 during mid-day trading on Friday. 34,717 shares of the company were exchanged, compared to its average volume of 238,900. Evoke Pharma has a 52 week low of $1.94 and a 52 week high of $10.79. The company has a 50 day simple moving average of $5.93 and a 200-day simple moving average of $4.69. The stock has a market capitalization of $16.67 million, a price-to-earnings ratio of -5.16 and a beta of -0.14.

Wall Street Analysts Forecast Growth

EVOK has been the topic of several recent research reports. Laidlaw lowered Evoke Pharma from a “buy” rating to a “hold” rating in a report on Thursday, November 6th. Wall Street Zen raised Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, September 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Evoke Pharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Evoke Pharma currently has an average rating of “Reduce”.

Insider Buying and Selling at Evoke Pharma

In other news, major shareholder Roger M. Klein sold 9,000 shares of Evoke Pharma stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $10.65, for a total value of $95,850.00. Following the completion of the transaction, the insider owned 29,000 shares in the company, valued at $308,850. This trade represents a 23.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.29% of the company’s stock.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. National Wealth Management Group LLC acquired a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 80,130 shares of the specialty pharmaceutical company’s stock, valued at approximately $398,000. National Wealth Management Group LLC owned 5.14% of Evoke Pharma at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.